Prognostic value of the proliferation marker Ki‐67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial

Rademakers, Saskia E.; Hoogsteen, Ilse J.; Rijken, P.F.J.W.; Terhaard, Chris H.J.; Doornaert, P.; Langendijk, Johannes A.; Ende, Piet van den; Kogel, Albert J. van der; Bussink, Johan; Kaanders, Johannes H.A.M.

doi:10.1002/hed.23569

Cited by 16 publications

(23 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also enhanced locoregional control and disease-free survival in anemic laryngeal cancer patients in addition to their quality of life after the treatment [106,107]. Likewise, ARCON was found to improve prognosis in patients with highly proliferative laryngeal cancers (detected with Ki-67 immunohistochemistry) [102]. In urinary bladder cancer, Hoskin et al performed a phase II clinical trial where ARCON was found to be relatively safe and well tolerated; in addition, the latter enhanced local regional control and improved overall survival [108,109].…”

Section: Soft Tissue/fibrosarcoma)mentioning

confidence: 89%

The Role of Nicotinamide in Cancer Chemoprevention and Therapy

2020

View full text Add to dashboard Cite

Nicotinamide (NAM) is a water-soluble form of Vitamin B3 (niacin) and a precursor of nicotinamide-adenine dinucleotide (NAD+) which regulates cellular energy metabolism. Except for its role in the production of adenosine triphosphate (ATP), NAD+ acts as a substrate for several enzymes including sirtuin 1 (SIRT1) and poly ADP-ribose polymerase 1 (PARP1). Notably, NAM is an inhibitor of both SIRT1 and PARP1. Accumulating evidence suggests that NAM plays a role in cancer prevention and therapy. Phase III clinical trials have confirmed its clinical efficacy for non-melanoma skin cancer chemoprevention or as an adjunct to radiotherapy against head and neck, laryngeal, and urinary bladder cancers. Evidence for other cancers has mostly been collected through preclinical research and, in its majority, is not yet evidence-based. NAM has potential as a safe, well-tolerated, and cost-effective agent to be used in cancer chemoprevention and therapy. However, more preclinical studies and clinical trials are needed to fully unravel its value.

show abstract

Section: Soft Tissue/fibrosarcoma)mentioning

confidence: 89%

The Role of Nicotinamide in Cancer Chemoprevention and Therapy

2020

View full text Add to dashboard Cite

show abstract

“…Ki-67, a gene located on chromosome 10, can detect a nuclear protein in the nuclear matrix of proliferating cells and its function has been shown to be associated with mitosis. In particular, closely associated with tumor cell proliferation ( 16 – 18 ). Currently, however, Ki-67 expression and its function in luminal breast cancer has not been completely elucidated.…”

Section: Discussionmentioning

confidence: 99%

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer

Yuan

Wang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

The aim of the present study was to examine Ki-67 expression in tissue of luminal type breast cancer and to investigate the association between the Ki-67 expression level and clinicopathology of breast cancer. A total of 62 patients with breast cancer were included in the study group, whereas 30 patients undergoing a health check-up who were diagnosed with breast hyperplasia were included in the control group. Levels of Ki-67 expression in patients of the two groups were assessed using fluorescent quantitative polymerase chain reaction. The association between Ki-67 and the clinicopathology of the cancer was investigated by analyzing cancer cell proliferation and migration by reducing Ki-67 expression in the human MCF-7 cancer cell line. Compared with the controls, Ki-67 expression was significantly increased in the serum and cancer tissue of breast cancer patients (P<0.05). Ki-67 mRNA expression was significantly higher in cancer tissue than that in the corresponding paracancerous tissue of breast cancer (P<0.05). In addition, a high expression of Ki-67 was positively correlated with the clinical staging of tumor, tumor size and lymphatic metastasis of breast cancer, with statistical significance (P<0.05). In MCF-7 cells with a reduced Ki-67 expression, the proliferation activity and migration of breast cancer cells were significantly reduced (P<0.05). In conclusion, Ki-67 may be involved in promoting the genesis and development of breast cancer by affecting the proliferation and migration of cancer cells.

show abstract

“…[13][14][15][16] The evaluation of Ki-67 expression has been performed using different cut-offs, varying from 10% to 60%. [17][18][19][20][21] Therefore, Ki-67 expression was evaluated using the median staining percentage (49%). Expression of β-Catenin was scored on both membranous as well as cytoplasmic staining.…”

Section: Evaluation Of Immunohistochemical Stainingmentioning

confidence: 99%

Distinct Biomarker Profiles and Clinical Characteristics in T1‐T2 Glottic and Supraglottic Carcinomas

et al. 2020

View full text Add to dashboard Cite

Background: In early stage laryngeal squamous cell carcinoma (LSCC) radiotherapy with curative intent is a major treatment modality. TNM classification is used to define patients eligible for radiotherapy. Studies in early stage glottic LSCC identified several predictive biomarkers associated with local control. However, we recently reported that this predictive value could not be confirmed in supraglottic LSCC. Objective: To examine whether clinical behavior and protein expression patterns of these biomarkers differ between glottic and supraglottic LSCC. Study Design: Retrospective cohort study. Methods: Tumor tissue sections of 196 glottic and 80 supraglottic T1-T2 LSCC treated primarily with RT were assessed immunohistochemically for expression of pAKT, Ki-67 and β-Catenin. Expression data of HIF-1α, CA-IX, OPN, FADD, pFADD, Cyclin D1, Cortactin and EGFR in the same cohort of glottic and supraglottic LSCC, were retrieved from previously reported data. The relationship between glottic and supraglottic sublocalization and clinicopathological, follow-up, and immunohistochemical staining characteristics were evaluated using logistic regression and Cox regression analyses. Results: Glottic LSCC were correlated with male gender (P = .001), hoarseness as a primary symptom (P < .001), T1 tumor stage (P < .001), negative lymph node status (P < .001), and an older age at presentation (P = .004). Supraglottic LSCC patients developed more post-treatment distant metastasis when adjusted for gender, age, and T-status. While supraglottic LSCC was associated with higher expression of HIF-1α (P = .001), Cortactin (P < .001), EGFR (P < .001), and Ki-67 (P = .027), glottic LSCC demonstrated higher expression of CA-IX (P = .005) and Cyclin D1 (P = .001). Conclusion: Differences in clinicopathological and immunohistochemical staining characteristics suggest that T1-T2 glottic and supraglottic LSCC should be considered as different entities.

show abstract

Prognostic value of the proliferation marker Ki‐67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial

Abstract: Patients with laryngeal carcinomas with high proliferative activity are at increased risk of regional and distant metastases formation. This risk can be reduced by treatment with ARCON.

Cited by 16 publications

References 17 publications

The Role of Nicotinamide in Cancer Chemoprevention and Therapy

The Role of Nicotinamide in Cancer Chemoprevention and Therapy

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer

Distinct Biomarker Profiles and Clinical Characteristics in T1‐T2 Glottic and Supraglottic Carcinomas

Contact Info

Product

Resources

About